125 related articles for article (PubMed ID: 932933)
21. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.
von Bahr C; Movin G; Nordin C; Lidén A; Hammarlund-Udenaes M; Hedberg A; Ring H; Sjöqvist F
Clin Pharmacol Ther; 1991 Mar; 49(3):234-40. PubMed ID: 2007317
[TBL] [Abstract][Full Text] [Related]
22. A study of the conversion of phenothiazine derivatives to the corresponding sulfoxides on thin-layer plates.
Kofoed J; Fabierkiewicz C; Lucas GH
J Chromatogr; 1966 Aug; 23(3):410-6. PubMed ID: 5969493
[No Abstract] [Full Text] [Related]
23. Artifacts in the analysis of thioridazine and other neuroleptics.
Eap CB; Koeb L; Baumann P
J Pharm Biomed Anal; 1993 Jun; 11(6):451-7. PubMed ID: 8104489
[TBL] [Abstract][Full Text] [Related]
24. Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity.
Llerena A; Berecz R; de la Rubia A; Norberto MJ; Benítez J
Ther Drug Monit; 2000 Aug; 22(4):397-401. PubMed ID: 10942178
[TBL] [Abstract][Full Text] [Related]
25. Light-induced racemization: artifacts in the analysis of the diastereoisomeric pairs of thioridazine 5-sulfoxide in the plasma and urine of patients treated with thioridazine.
Eap CB; Souche A; Koeb L; Baumann P
Ther Drug Monit; 1991 Jul; 13(4):356-62. PubMed ID: 1780970
[TBL] [Abstract][Full Text] [Related]
26. Partitioning of thioridazine and mesoridazine in human blood fractions.
Dinovo EC; Pollak H; Gottschalk LA
Methods Find Exp Clin Pharmacol; 1984 Mar; 6(3):143-6. PubMed ID: 6748818
[TBL] [Abstract][Full Text] [Related]
27. Identification of lactams as in vitro metabolites of piperidine-type phenothiazine antipsychotic drugs.
Lin G; Chu KW; Damani LA; Hawes EM; Midha KK
J Pharm Biomed Anal; 1996 Apr; 14(6):727-38. PubMed ID: 8807548
[TBL] [Abstract][Full Text] [Related]
28. Measurement of thioridazine in blood and urine.
Ng CH; Crammer JL
Br J Clin Pharmacol; 1977 Apr; 4(2):173-83. PubMed ID: 16633
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses.
Salih IS; Thanacoody RH; McKay GA; Thomas SH
Clin Pharmacol Ther; 2007 Nov; 82(5):548-54. PubMed ID: 17410120
[TBL] [Abstract][Full Text] [Related]
30. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.
Berecz R; de la Rubia A; Dorado P; Fernández-Salguero P; Dahl ML; LLerena A
Eur J Clin Pharmacol; 2003 May; 59(1):45-50. PubMed ID: 12682803
[TBL] [Abstract][Full Text] [Related]
31. Combination of experimental and in silico methods for the assessment of the phototransformation products of the antipsychotic drug/metabolite Mesoridazine.
Wilde ML; Menz J; Leder C; Kümmerer K
Sci Total Environ; 2018 Mar; 618():697-711. PubMed ID: 29055596
[TBL] [Abstract][Full Text] [Related]
32. Thioridazine pharmacodynamics: clinical effects may depend upon drug metabolism.
Lewis MH; Mobilio JN; Rissmiller DJ; Mailman RB
J Am Osteopath Assoc; 1984 Sep; 84(1 Suppl):124-8. PubMed ID: 6490416
[No Abstract] [Full Text] [Related]
33. Mesoridazine -- a pharmacodynamic and pharmacokinetic profile.
Gershon S; Sakalis G; Bowers PA
J Clin Psychiatry; 1981 Dec; 42(12):463-9. PubMed ID: 7031039
[TBL] [Abstract][Full Text] [Related]
34. A method for the fluorimetric determination of thioridazine (Mellaril) or mesoridazine (Lidanil) in plasma.
Pacha WL
Experientia; 1969 Jan; 25(1):103-4. PubMed ID: 5766556
[No Abstract] [Full Text] [Related]
35. Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment.
Daniel WA; Syrek M; Mach A; Wójcikowski J; Boksa J
Pol J Pharmacol; 1997; 49(6):439-52. PubMed ID: 9566048
[TBL] [Abstract][Full Text] [Related]
36. Development of a radioimmunoassay procedure for mesoridazine and its comparison with a high-performance liquid chromatographic method.
Chakraborty BS; Hawes EM; Midha KK
Ther Drug Monit; 1987 Dec; 9(4):464-71. PubMed ID: 3424415
[TBL] [Abstract][Full Text] [Related]
37. The assay of plasma concentration of thioridazine and its metabolites as a function of time.
Gottschalk LA; Dinovo EC; Nandi BR
Commun Psychopharmacol; 1978; 2(6):475-9. PubMed ID: 747914
[No Abstract] [Full Text] [Related]
38. No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients.
Dorado P; Berecz R; Peñas-Lledó EM; de la Rubia A; Llerena A
Eur J Clin Pharmacol; 2007 May; 63(5):527-8. PubMed ID: 17345072
[No Abstract] [Full Text] [Related]
39. Radioreceptor assay and high-performance liquid chromatography yield similar results for serum thioridazine and its major metabolites.
Rao ML; Brown WA; Wagner R
Ther Drug Monit; 1988; 10(2):184-7. PubMed ID: 3381236
[TBL] [Abstract][Full Text] [Related]
40. Plasma and red cell levels of thioridazine and clinical response in schizophrenia.
Smith RC; Baumgartner R; Ravichandran GK; Shvartsburd A; Schoolar JC; Allen P; Johnson R
Psychiatry Res; 1984 Aug; 12(4):287-96. PubMed ID: 6594712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
